The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.
On Tuesday, the antibiotic Xacduro was approved by the US Food and Drug Administration (FDA) to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii-calcoaceticus (ABC) in patients 18 years of age and older.
Xacduro (sulbactam-durlobactam; SUL-DUR) is an intravenous investigational therapy that is a combination of sulbactam, an IV β-lactam antibiotic, and durlobactam, a novel broad-spectrum IV β-lactamase inhibitor. SUL-DUR targets ABC infections, including those caused by multidrug-resistant and carbapenem-resistant (CRAB) strains.
Contagion has been following this exciting new agent for a while and has compiled 5 of our most recent and relevant pieces of content. Dive into these clinical trials and interviews with experts to learn more about how Xacduro could be a game-changer in the fight against highly resistant pathogens.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.